The Oncology InstituteTOIIW 56 Return-on-Tangible-Asset is -6.71% as of Mar. 2026. GuruFocus rates TOIIW with a GF Score™ of 56/100. The stock has 6 warning signs investors should review. Among 684 Healthcare Providers & Services companies, The Oncology Institute ranks worse than 82.02% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. The Oncology Institute's annualizedNet Income for the quarter that ended in Mar. 2026 was $-9.97 Mil. The Oncology Institute's average total tangible assets for the quarter that ended in Mar. 2026 was $148.56 Mil. Therefore, The Oncology Institute's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -6.71%.
The historical rank and industry rank for The Oncology Institute's Return-on-Tangible-Asset or its related term are showing as below:
TOIIW'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -51.72 Med: -38.63 Max: 0.08
Current: -30.02
During the past 8 years, The Oncology Institute's highest Return-on-Tangible-Asset was 0.08%. The lowest was -51.72%. And the median was -38.63%.
TOIIW's Return-on-Tangible-Asset is ranked worse than 82.02% of 684
companies
in the Healthcare Providers & Services industry
Industry Median: 2.43
vs TOIIW: -30.02
The Oncology Institute (NAS:TOIIW) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
The Oncology Institute Return-on-Tangible-Asset Related Terms
The Oncology Institute Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for The Oncology Institute's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute Return-on-Tangible-Asset Chart
TOIIW vs CYH, SRTA, CCRN: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, The Oncology Institute's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Oncology Institute Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -6.71% mean?
The Oncology Institute (TOIIW) has a Return-on-Tangible-Asset of -6.71% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on The Oncology Institute and its competitors. According to the industry distribution chart, The Oncology Institute ranks #561 out of 684 companies in the Healthcare Providers & Services industry, placing it in the top 82%.
Is The Oncology Institute's Return-on-Tangible-Asset too high?
The Oncology Institute's current Return-on-Tangible-Asset is -6.71%. Based on the distribution chart, The Oncology Institute ranks #561 out of 684 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, The Oncology Institute has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's Return-on-Tangible-Asset compare to CYH and SRTA?
According to the Healthcare Providers & Services industry distribution chart, The Oncology Institute ranks #561 out of 684 companies for Return-on-Tangible-Asset. This places The Oncology Institute in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.43, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on The Oncology Institute and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Oncology Institute's current Return-on-Tangible-Asset is -6.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current Return-on-Tangible-Asset of -6.71%. The current Return-on-Tangible-Asset is -6.71%. The Oncology Institute's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current Return-on-Tangible-Asset is -6.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for TOIIW
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOIIW has been successfully added to your 
